Review of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
|
|
|
- Diana Briggs
- 5 years ago
- Views:
Transcription
1
2 Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology
3 Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated phosphoprotein, expressed on immature and mature B cells European Society for Organ Transplantation. Published by Blackwell Publishing Ltd 26 (2013)
4 Rituximab is a chimeric anti-cd20 monoclonal antibody
5 Rituximab causes a reduction in B cells in the peripheral blood within 1 3 days of administration, and complete B cell depletion in the majority of patients within 1 6 weeks. It does not have a direct effect on plasma cells European Society for Organ Transplantation. Published by Blackwell Publishing Ltd 26 (2013)
6 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, ABO incompatible kidney transplantation B) Induction therapy C) Treatment of Acute and Chronic Antibody Mediated Rejection D) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant, E) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
7 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, ABO incompatible kidney transplantation B) Induction therapy B) Treatment of Acute and Chronic Antibody Mediated Rejection C) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant, D) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
8
9
10
11
12
13
14
15 Conclusions These findings suggest that the combination of intravenous immune globulin and rituximab may prove effective as a desensitization regimen for patients awaiting a transplant from either a living donor or a deceased donor. Larger and longer trials are needed to evaluate the clinical efficacy and safety of this approach.
16 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, ABO incompatible kidney transplantation B) Induction therapy C) Treatment of Acute and Chronic Antibody Mediated Rejection D) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant, E) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
17 Clinical use of rituximab in renal transplantation induction therapy B cells play a central role in the formation of Tertiary Lymphoid Organs (TLOs) and the modulation of chronic rejection. Rituximab leads to a reduction in B cells within allografts when given as induction therapy, and also when given as treatment for rejection. An association between improvement in allograft function and reduction in B cells after rituximab treatment for rejection has been described European Society for Organ Transplantation. Published by Blackwell Publishing Ltd 26 (2013)
18
19
20 In conclusion we demonstrated that pretransplantation induction with rituximab could significantly decrease AMR and increase graft survival rates in sensitized patients undergoing kidney transplantation.
21 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, ABO incompatible kidney transplantation B) Induction therapy C) Treatment of Acute and Chronic Antibody Mediated Rejection D) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant, E) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
22
23
24 Acute rejection with or without de novo DSA : impact upon kidney allograft survival If DSA does appear at the time of acute rejection Allograft survival p= 0,001 Rapid decrease in DSA following specific therapy Improvement in allograft survival -24- Everly MJ & al. Am J Transplant. 2009;9:
25 AMR Acute antibody-mediated rejection (AMR) is characterized by acute graft dysfunction, histologic evidence of acute tissue injury, deposition of C4d in peritubular capillaries, and the presence of donor-specific antibodies (DSAs). Acute AMR can be arbitrarily divided into early (occurring within 6 months of renal transplantation) or late (occurring after 6 months of renal transplantation).
26 AMR Acute ABMR, has been reported to occur in up to 7% of patients but can be as high as 50% in patients with HLA incompatible transplants. It can have over a four-fold risk of graft loss compared to matched controls and many of these patients go on to develop transplant glomerulopathy or other features of chronic antibody-mediated rejection (cabmr) X/ 2016 Elsevier Inc. All rights
27 Types of Antibody-Mediated Rejection (AMR) Hyperacute AMR. It occurs due to preformed donor specific antibodies (DSA) present in high titers and presents as graft failure that can occur within minutes (but sometimes may be delayed for a few days) after transplantation.
28 Hyperacute AMR The histopathology is characterized by features of severe endothelial and arterial injury manifested as arteritis (often transmural), interstitial edema, and severe cortical necrosis, with almost all cases requiring allograft nephrectomy. Most of the initial cases were reported in patients with a history of previous transplantation or in multiparous women, suggesting the role of sensitization and preformed antibodies.
29 Acute AMR It is characterized by graft dysfunction manifesting over days and is a result of DSAs, that may either be preformed or develop denovo after transplantation. Acute AMR occurs in about 5 7% of all kidney transplants and is responsible for 20 48% of acute rejection episodes among presensitized positive crossmatch patients. Histopathology in these patients is again related to endothelial injury mediated by antibodies but is less severe than that seen in hyperacute rejections.
30 AMR According to the Banff 2013 classification,all of the following 3 features are required for the diagnosis of acute AMR: Histologic evidence of acute tissue injury defined by the presence of one or more of the following: 1. a. Glomerulitis (g >0) or peritubular capillaritis (ptc >0) b. Intimal or transmural arteritis (v >0) c. Acute thrombotic microangiopathy (TMA) of no other obvious cause d. Acute tubular injury of no other obvious cause Ochsner Journal 17:46 55, 2017 Academic Division of Ochsner Clinic Foundation
31 AMR 2. Histologic evidence of current/recent antibody interaction with vascular endothelium, defined by at least one of the following: a. Linear C4d staining in the peritubular capillaries b. Moderate microvascular inflammation c. Increased expression of tissue gene transcripts indicative of endothelial injury 3. Detection of DSAs (HLA or non-hla) in the serum Ochsner Journal 17:46 55, 2017 Academic Division of Ochsner Clinic
32 Diagnosis of AMR Based on the histopathology, AMR can be classified into three subtypes as below. Class I: Presence of acute tubular necrosis (ATN) only, with minimal inflammation. Class II: glomerulitis, peritubular capillaritis, and microthrombosis. Class III: Arteritis.
33 Chronic AMR Acute AMR has been shown to be a major risk factor for the development of chronic AMR. According to the revised Banff 2013 classification,the diagnosis of chronic, active AMR requires 3 features: 1. Histologic evidence of chronic tissue injury, defined by the presence of at least one of the following: a. Transplant glomerulopathy b. b. Severe peritubular capillary basement membrane multilayering identified by electron microscopy c. New-onset arterial intimal fibrosis with no other known etiology Ochsner Journal 17:46 55, 2017 Academic Division of Ochsner Clinic Foundation
34 Chronic AMR 2. Histologic evidence of antibody interaction with vascular endothelium, defined by the presence of at least one of the following: a. Linear C4d staining in the peritubular capillaries b. Moderate microvascular inflammation c. Increased expression of tissue gene transcripts indicative of endothelial injury 3. Detection of DSAs (HLA or non-hla) in the serum Ochsner Journal 17:46 55, 2017 Academic Division of Ochsner Clinic Foundation
35 Chronic AMR It is now well recognized that antibodies can mediate chronic allograft injury which is characteristically seen as transplant glomerulopathy (TG) on kidney biopsies. TG (also known as or chronic allograft glomerulopathy) is characterized by : glomerular mesangial expansion capillary basement membrane (BM) duplication, seen as basement membrane double contouring or splitting. Similarly,the peritubular capillary (PTC) basement membrane also shows changes, but these are seen mostly on electron microscopy sections as basement membrane multilayering.
36 Chronic AMR Clinically, the manifestations : Asymptomatic Nephrotic range proteinuria, Hypertension, Allograft dysfunction Progression can sometimes be fairly rapid, especially with ongoing acute AMR, resulting in graft failure Within months. The prevalence of TG in protocol biopsies has varied between 5% at 1 yr to 20% at 5 years.
37 Treatment The primary goal in AMR treatment : Reduction/ removal of DSAs Elimination of the B-cell/plasma cell population responsible for the production of these antibodies.
38 Prevention and treatment of antibody-mediated rejection after kidney transplantation Anti-humoral treatment concepts: most protocols combine two major therapeutic principles: (a) apheresis for antibody depletion and (b) modulation of B cell immunity and other components of adaptive and innate immunity Bartel G et al. Transplant Int, 2011;24:
39
40
41
42 Conclusion This meta-analysis of 10 studies, including 249 patients, suggests that treatment with RTX is associated with improved graft out come in patients with AMR of the transplanted kidney.
43 Treatment Rituximab. The mechanism of action of Rituximab in AMR is not clear, given that the plasma cells do not express CD20 on their surface. The depletion of CD20-positive subset of B-cells may attenuate the antibody generation process. The standard dosing of Rituximab is 375 mg/m2/wk for 2 4 weeks.
44
45
46 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, ABO incompatible kidney transplantation B) Induction therapy C) Treatment of Acute and Chronic Antibody Mediated Rejection D) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant E) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
47 Kidney International (2017) 92,
48 Kidney International (2017) 92,
49 Kidney International (2017) 92,
50 Kidney International (2017) 92,
51
52
53
54
55
56 Results & Conclusions The incidence of recurrent imn was 44%, and recurrences occurred at a median time of 13.6 months after transplantation. Two patterns of recurrence were identified: Early and late. No predictors of recurrence or disease progression could be identified. Treatment with rituximab was effective in four of four patients in stabilizing or reducing proteinuria and stabilizing renal function. Recurrence of imn is common even in the era of modern immunosuppression. Rituximab seems to be a valuable treatment option for these patients, although larger studies are needed to confirm our data. Clin J Am Soc Nephrol 5: , doi: /CJN
57 Clinical use of rituximab in renal transplantation A) Desensitization protocols for highly sensitized recipients prior to or concurrent with kidney transplantation, B) ABO incompatible kidney transplantation C) Treatment of Acute and Chronic Antibody Mediated Rejection D) Treatment of Recurrent and de novo Glomerular Diseases after kidney transplant, E) Treatment of Post transplant Lymphoproliferative Disorder (PTLD). Transplantation Jan; Anti-CD20 Blocker Rituximab in Kidney Transplantation. Sood P1, Hariharan S1.
58
59
60 In conclusion Monotherapy with monoclonal antibody rituximab is a safe and effective treatment for patients with PTLD following solid organ transplantation. The efficacy of monotherapy with rituximab in PTLD patients is superior to that achieved in non-transplanted patients with aggressive B-cell lymphomas. Rituximab proved to be well tolerated and effective in the treatment of PTLD.
61 بادتشک هجوت نسح زا ر ا هجوت نسح ز حس هجوت ن توج ه شما
Statement of Disclosure
Statement of Disclosure Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma Treatment of Acute ABMR AstraZeneca Treatment
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Statement of Disclosure Mark
Kidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA
Kidney Summary Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Key Issues to Address re: the Classification 1. Incorporation of i-ifta + tubulitis into the TCMR classification - Defining
HLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
Management of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic
Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney
Biopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Biopsy Features of Kidney Allograft Rejection Banff 2017 B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Treatment of allograft dysfunction should rely on the biopsy findings
Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients
Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients Lorriana Leard, MD UCSF Transplant Pulmonologist Associate Professor of Clinical Medicine Vice Chief of Clinical Activities Pulmonary, Critical
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
Update on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University of Tennessee Health Science Center
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
Update on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Methodist University Hospital, Transplant Institute Division of Transplantation, Department
RENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
HLA Part II: My Patient Has DSA, Now What?
2017 CST-Astellas Canadian Transplant Fellows Symposium HLA Part II: My Patient Has DSA, Now What? James Lan, MD, FRCPC, D(ABHI) Dr. Lan completed his nephrology training at the University of British Columbia.
Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification
Banff 1 Banff Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital Morozumi Kunio,
No evidence of C4d association with AMR However, C3d and AMR correlated well
C4d positivity Poor prognostic factor Reversal to C4d negativity did not change prognosis, with current therapy Prognostic factor for CAV Variable time line for CAV/death No correlation with cellular rejection
DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
Case Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
Interstitial Inflammation
Interstitial Inflammation Currently considered to be T cell-mediated process Plasma cell rich acute rejection often associated with AMR Preliminary data suggests that interstitial follicular helper T cells
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
AMR in Liver Transplantation: Incidence
AMR in Liver Transplantation: Incidence Primary AMR 1/3 to 1/2 of ABO-incompatible transplants Uncommon with ABO-compatible transplant Secondary AMR Unknown incidence: rarely tested Why is AMR uncommon
Antibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305
Antibody-Mediated Rejection in the Lung Allograft Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Gerald J Berry, MD Professor of Pathology Stanford University, Stanford, CA
Histopathological findings in transplanted kidneys
Katsuma et al. Renal Replacement Therapy (2017) 3:6 DOI 10.1186/s41100-016-0089-0 REVIEW Histopathological findings in transplanted kidneys Ai Katsuma, Takafumi Yamakawa, Yasuyuki Nakada, Izumi Yamamoto
Diagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
Pathology of Kidney Allograft Dysfunction. B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Pathology of Kidney Allograft Dysfunction B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary The gold standard for exploration of the cause of an allograft dysfunction is to perform
Solid Organ Transplant
Solid Organ Transplant Lee R. Goldberg, MD, MPH, FACC Associate Professor of Medicine Medical Director, Heart Failure and CardiacTransplant Program University of Pennsylvania Disclosures Thoratec Consulting
The Banff Conferences on renal allograft pathology the latest 2013 report
615245PSH0010.1177/2010105815615245Proceedings of Singapore HealthcareLoh research-article2015 Review Article PROCEEDINGS OF SINGAPORE HEALTHCARE The Banff Conferences on renal allograft pathology the
Interpretation of Renal Transplant Biopsy. Arthur H. Cohen Wake Forest University School of Medicine Winston-Salem, North Carolina USA
Interpretation of Renal Transplant Biopsy Arthur H. Cohen Wake Forest University School of Medicine Winston-Salem, North Carolina USA Renal Transplant Biopsies Tissue Processing Ideal world process as
Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
Acute renal failure (ARF) in the transplanted kidney represents a
Acute Renal Failure in the Transplanted Kidney Kim Solez Lorraine C. Racusen Acute renal failure (ARF) in the transplanted kidney represents a high-stakes area of nephrology and of transplantation practice.
Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management
Curr Transpl Rep (2014) 1:78 85 DOI 10.1007/s40472-014-0012-y KIDNEY TRANSPLANTATION (ML HENRY, SECTION EDITOR) Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management Carrie
Immunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting Antibody-Mediated Rejection
Clinical and Developmental Immunology Volume 2013, Article ID 460316, 6 pages http://dx.doi.org/10.1155/2013/460316 Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting
Histopathological evaluation of renal allograft biopsies in Nepal: interpretation and significance
Nepal Medical Association Building Exhibition Road, Kathmandu Journal of Pathology of Nepal (2012) Vol. 2, 172-179 Association of Clinical Pathologist of Nepal-2010 Journal of PATHOLOGY of Nepal www.acpnepal.com
Transfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies
American Journal of Transplantation 2013; 13: 485 492 Wiley Periodicals Inc. Brief Communication C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
Case Report A Clinical and Pathological Variant of Acute Transplant Glomerulopathy
Case Report A Clinical and Pathological Variant of Acute Transplant Glomerulopathy Miklos Z. Molnar, 1 G. V. Ramesh Prasad, 2 Darren A. Yuen, 2,3 Serge Jothy, 4 and Jeffrey S. Zaltzman 2,5 1 Division of
Medicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients Hyeyoung Lee, MD,
Pathology of Kidney Allograft Dysfunction. B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Pathology of Kidney Allograft Dysfunction B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary The renal biopsy is a powerful tool in the diagnostic evaluation of allograft dysfunction
Dr Ian Roberts Oxford
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing renal failure Highlight diagnostic pitfalls. Crescentic GN: renal
Since the first Banff meeting in 1991, the diagnosis and
CLINICAL AND TRANSLATIONAL RESEARCH Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d Michelle Willicombe, 1,5 Candice Roufosse, 2 Paul Brookes, 3 Adam G. McLean 1, Jack Galliford,
Pros and cons for C4d as a biomarker
review http://www.kidney-international.org & 2012 International Society of Nephrology Pros and cons for C4d as a biomarker Danielle Cohen 1, Robert B. Colvin 2, Mohamed R. Daha 3, Cinthia B. Drachenberg
Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH
Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH
Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance
ORIGINAL ARTICLE Port J Nephrol Hypert 2008; 22(1): 37-42 Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance Helena
Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
Chronic injury to the microcirculation in EMB
Chronic injury to the microcirculation in EMB Dylan V Miller MD M Patricia Revelo MD Disclosures Miller: None Revelo: None Goals & Objectives Characterize the tissue-level pathologic changes occurring
Recognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
Kidney Transplant. November 4 th, 2016
Kidney Transplant November 4 th, 2016 Brad West, MD, FACP Medical Director of Transplant Services, Memorial Medical Center Chairman Department of Nephrology, Springfield Clinic 1 Adjusted survival: 1993-1997
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT HISTOPATHOLOGIC DISORDERS AFFECTING THE ALLOGRAFT OTHER THAN REJECTION RECURRENT DISEASE DE NOVO DISEASE TRANSPLANT GLOMERULOPATHY Glomerular Non-glomerular
(Universal Activity Number H01- P) Please note: If you participated in the activity with UAN L01- P, you are
CME Information Release Date: January 2, 2018 Expiration Date: January 2, 2019 UAN Live Release Date: June 12, 2016 Estimated Time to Complete this Activity: 1.25 hours Overview This article reviews the
Special thanks to our clinical collaborators Special thanks to our patients. Administration. Andre Baretto
Antibody-mediated rejection: a prototype for antibody-mediated diseases Phil Halloran Alberta Transplant Applied Genomics Centre Edmonton, Canada Disclosures PFH has shares in TSI a university spinoff
Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
The multidisciplinary approach to AMR in lung transplantation: Reaching a consensus. Deborah Jo Levine Professor of Medicine University of Texas
The multidisciplinary approach to AMR in lung transplantation: Reaching a consensus Deborah Jo Levine Professor of Medicine University of Texas Disclosures I have no financial relations with any relevant
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique. Mark D. Stegall Mayo Clinic, Rochester, MN
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique Mark D. Stegall Mayo Clinic, Rochester, MN Disclosure. Dr Mark Stegall. Institution : Mayo Clinic, Rochester. Research contracts
HHS Public Access Author manuscript Pediatr Transplant. Author manuscript; available in PMC 2017 November 01.
Persistent C4d and Antibody-Mediated Rejection in Pediatric Renal Transplant Patients Andrew M. South, MD, MS a,b, Lynn Maestretti, MPH, MMS, PA-C c, Neeraja Kambham, MD d, Paul C. Grimm, MD e, and Abanti
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology The Harvard community has made this article openly available. Please
Treatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients
New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients Denis Glotz, MD, PhD Saint-Louis Hospital Paris, France Robert A. Montgomery, MD, DPhil, FACS The Johns
Correspondence should be addressed to Chul Woo Yang;
Immunology Research, Article ID 828732, 7 pages http://dx.doi.org/10.1155/2014/828732 Clinical Study The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of
TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding
Antibody Mediated Rejection (AMR) in Heart Transplantation Session
Page 1 Antibody Mediated Rejection (AMR) in Heart Transplantation Session Dear Colleagues: The Heart session at Banff this year will be solely focused on AMR and besides the fact that many of us attending
ACCME/Disclosure. Case #1. Case History. Dr. Bracamonte has nothing to disclose
Case #1 ACCME/Disclosure Dr. Erika Bracamonte Associate Professor of Pathology University of Arizona, College of Medicine Banner University Medical Center, Tucson Dr. Bracamonte has nothing to disclose
Introduction and Overview of the Current Landscape on Organ Donation and Transplantation in Canada Jag Gill, MD
2017 CST-Astellas Canadian Transplant Fellows Symposium Introduction and Overview of the Current Landscape on Organ Donation and Transplantation in Canada Jag Gill, MD Dr. Gill graduated from Medicine
Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service
Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service 1. Introduction Transplantation offers better survival and quality
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
New possibilities to improve the outcomes of renal transplantation
New possibilities to improve the outcomes of renal transplantation Ph.D. Thesis Zsolt J. Káposztás, MD Department of Surgery Medical Faculty University of Pécs Program leader: Professor Örs Péter Horváth
IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
DSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts
Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Peter Liptak and Bela Ivanyi* SUMMARY Calcineurin inhibitors (ciclosporin and tacrolimus) can cause acute and chronic nephrotoxicity.
OBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
Why Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
Issues in solid-organ transplantation in children: translational research from bench to bedside
REVIEW Issues in solid-organ transplantation in children: translational research from bench to bedside Steven E. Lipshultz, I,II,VI * Jayanthi J. Chandar, III Paolo G. Rusconi, II Alessia Fornoni, III
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university
ABO mismatched Renal Transplants
ABO mismatched Renal Transplants Nicos Kessaris Renal Transplant Surgeon St George s Hospital, London 7 th March 2012 Why? Protocol Risks Experience abroad Experience in UK Experience at St George s Conclusions
Transplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker
Treatment of Detected Antibodies Sean Pinney, MD Director, Advanced Heart Failure & Transplantation Mount Sinai Hospital New York, NY Sean Pinney, MD Associate Professor of Medicine Icahn School of Medicine
Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,
A Acute antibody-mediated rejection (Acute AMR) clinical features, 203 clinicopathologic correlations, 206 pathogenesis, 205 206 204 205 light microscopy, 203 204 Acute cellular rejection (ACR) clinical
Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss
http://www.kidney-international.org 2015 International Society of Nephrology see commentary on page 218 The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk
Strategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 Adriana Zeevi PhD (D) ABHI Professor of Pathology, Surgery and Immunology Director of Histocompatibility Laboratory University of Pittsburgh
RevIeWS. Sensitized renal transplant recipients: current protocols and future directions. James Gloor and Mark D. Stegall
RevIeWS Sensitized renal transplant recipients: current protocols and future directions James Gloor and Mark D. Stegall Abstract The identification of suitable donor kidneys for transplant candidates with
Review Article Antibody-Mediated Rejection in Kidney Transplantation: A Review
Journal of Transplantation Volume 2012, Article ID 193724, 9 pages doi:10.1155/2012/193724 Review Article Antibody-Mediated Rejection in Kidney Transplantation: A Review Chethan Puttarajappa, 1 Ron Shapiro,
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Dissertation Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Consultant: Official
Overview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
Deján Dobi, MD. PhD Thesis
Clinicopathologic Relevance of Vascular Changes Associated with Transplant Glomerulopathy Secondary to Chronic Antibody-mediated Rejection in the Renal Allograft Deján Dobi, MD PhD Thesis Szeged, 2018
Pathology of Complement Mediated Renal Disease
Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement
IMMUNOSUPPRESSIVE THERAPY Overview. Desensitization
IMMUNOSUPPRESSIVE THERAPY Overview Two types of immune responses to allografts: Cellular response: foreign antigen recognition activate antigen-specific lymphocytes (T-cells) o Key mediator: T-cells o
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
Figure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
Literature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of